Does PANITUMUMAB Cause Second primary malignancy? 8 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 8 reports of Second primary malignancy have been filed in association with PANITUMUMAB (Vectibix). This represents 0.1% of all adverse event reports for PANITUMUMAB.
8
Reports of Second primary malignancy with PANITUMUMAB
0.1%
of all PANITUMUMAB reports
3
Deaths
0
Hospitalizations
How Dangerous Is Second primary malignancy From PANITUMUMAB?
Of the 8 reports, 3 (37.5%) resulted in death.
Is Second primary malignancy Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for PANITUMUMAB. However, 8 reports have been filed with the FAERS database.
What Other Side Effects Does PANITUMUMAB Cause?
Rash (1,392)
Diarrhoea (1,123)
Death (767)
Dermatitis acneiform (758)
Neutropenia (757)
Skin toxicity (728)
Neuropathy peripheral (613)
Hypomagnesaemia (611)
Nausea (608)
Disease progression (600)
What Other Drugs Cause Second primary malignancy?
CYCLOPHOSPHAMIDE (1,247)
DOXORUBICIN (1,151)
VINCRISTINE (908)
IMATINIB (763)
PALBOCICLIB (658)
RITUXIMAB (646)
RUXOLITINIB (611)
ETOPOSIDE (573)
PREDNISONE (517)
OCTREOTIDE (496)
Which PANITUMUMAB Alternatives Have Lower Second primary malignancy Risk?
PANITUMUMAB vs PANOBINOSTAT
PANITUMUMAB vs PANTOPRAZOLE
PANITUMUMAB vs PANTOPRAZOLE ANHYDROUS
PANITUMUMAB vs PANTOTHENIC ACID
PANITUMUMAB vs PAPAVERINE